Document is current
Any future updates will be listed below
-
Authors
Aiyegbusi, Olalekan Lee
McMullan, Christel
Hughes, Sarah E.
Turner, Grace M.
Haroon, Shamil
Hotham, Richard
Brown, Kirsty
Alder, Yvonne
Agyen, Lisa
Buckland, Lewis
Camaradou, Jennifer
Chong, Amy
Jeyes, Felicity
Matthews, Karen L.
Moore, Patricia
Ormerod, Jane
Price, Gary
Saint-Cricq, Michael
Stanton, David
Walker, Anita
Calvert, Melanie J.
-
Funding
Funding for this research was provided by:
National Institute for Health and Care Research (COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013, COV-LT-0013)
- License Information
-
More Information
Article History
Received: 8 September 2024
Accepted: 30 October 2024
First Online: 9 November 2024
Declarations
:
: This project was approved by the HRA and the West Midlands Solihull-Research Ethics Committee (IRAS project ID:296374; REC reference: 21/WM/0203).
: Not applicable.
: OLA receives funding from the NIHR Birmingham Biomedical Research Centre (BRC), NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham and University Hospitals Birmingham NHS Foundation, LifeArc, Innovate UK (part of UK Research and Innovation), The Health Foundation, Gilead Sciences Ltd, Merck, Anthony Nolan, GSK, and Sarcoma UK. He declares personal fees from Gilead Sciences, Merck, Innovate UK, and GSK outside the submitted work. SEH receives funding from the NIHR Applied Research Collaboration (ARC), West Midlands, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics at the University of Birmingham, and Anthony Nolan. SEH declares personal fees from Cochlear Ltd and Aparito Ltd outside the submitted work. CM receives funding from the National Institute for Health Research (NIHR) Surgical Reconstruction and Microbiology Research Centre, the NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, CIS Oncology, Innovate UK, Anthony Nolan and has received personal fees from Aparito Ltd outside the submitted work. KLM is a Trustee and volunteer at Long Covid SOS. She is on the Long Covid Advisory Board for Dysautonomia International. She is employed by the NIHR. JC receives funding from NIHR on PPI from a study at UCL (NIHR132914) and a study at University Hospitals Bristol (NIHR203304). JC is a lay member on the NICE covid-19 expert panel and a citizen partner on the COVID END Evidence Synthesis Global Horizon Scanning panel. JC declares personal fees from MEDABLE, GlaxoSmithKline and Roche Canada outside of submitted work. SH receives funding from NIHR and UKRI. MJC received personal fees from Astellas, Boehringer Ingelheim, Aparito Ltd, CIS Oncology, Gilead, Halfloop, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK, Vertex and the Patient-Centered Outcomes Research Institute (PCORI) outside the submitted work. In addition, a family member owns shares in GSK. MJC receives funding from the NIHR Birmingham Biomedical Research Centre, NIHR Surgical Reconstruction and Microbiology Research Centre, NIHR Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, and NIHR ARC West Midlands at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, LifeArc, Health Data Research UK, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, European Regional Development Fund–Demand Hub, SPINE UK, UKRI, UCB Pharma, GSK, Anthony Nolan, and Gilead Sciences. All other authors declare no competing interests.
